Structure Therapeutics (GPCR) Competitors $24.15 -0.52 (-2.11%) Closing price 04:00 PM EasternExtended Trading$24.06 -0.09 (-0.36%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GPCR vs. TLX, TGTX, GRFS, LNTH, AXSM, NUVL, LEGN, ADMA, PCVX, and RYTMShould you be buying Structure Therapeutics stock or one of its competitors? The main competitors of Structure Therapeutics include Telix Pharmaceuticals Limited American Depositary Shares (TLX), TG Therapeutics (TGTX), Grifols (GRFS), Lantheus (LNTH), Axsome Therapeutics (AXSM), Nuvalent (NUVL), Legend Biotech (LEGN), ADMA Biologics (ADMA), Vaxcyte (PCVX), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry. Structure Therapeutics vs. Telix Pharmaceuticals Limited American Depositary Shares TG Therapeutics Grifols Lantheus Axsome Therapeutics Nuvalent Legend Biotech ADMA Biologics Vaxcyte Rhythm Pharmaceuticals Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability, risk and community ranking. Is TLX or GPCR more profitable? Telix Pharmaceuticals Limited American Depositary Shares' return on equity of 0.00% beat Structure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Telix Pharmaceuticals Limited American Depositary SharesN/A N/A N/A Structure Therapeutics N/A -16.37%-15.68% Do analysts prefer TLX or GPCR? Telix Pharmaceuticals Limited American Depositary Shares presently has a consensus price target of $22.00, indicating a potential upside of 32.61%. Structure Therapeutics has a consensus price target of $79.86, indicating a potential upside of 230.67%. Given Structure Therapeutics' higher probable upside, analysts plainly believe Structure Therapeutics is more favorable than Telix Pharmaceuticals Limited American Depositary Shares.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telix Pharmaceuticals Limited American Depositary Shares 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Structure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer TLX or GPCR? Structure Therapeutics received 30 more outperform votes than Telix Pharmaceuticals Limited American Depositary Shares when rated by MarketBeat users. However, 100.00% of users gave Telix Pharmaceuticals Limited American Depositary Shares an outperform vote while only 89.47% of users gave Structure Therapeutics an outperform vote. CompanyUnderperformOutperformTelix Pharmaceuticals Limited American Depositary SharesOutperform Votes4100.00% Underperform VotesNo VotesStructure TherapeuticsOutperform Votes3489.47% Underperform Votes410.53% Does the media refer more to TLX or GPCR? In the previous week, Structure Therapeutics had 13 more articles in the media than Telix Pharmaceuticals Limited American Depositary Shares. MarketBeat recorded 13 mentions for Structure Therapeutics and 0 mentions for Telix Pharmaceuticals Limited American Depositary Shares. Telix Pharmaceuticals Limited American Depositary Shares' average media sentiment score of 1.27 beat Structure Therapeutics' score of 0.58 indicating that Telix Pharmaceuticals Limited American Depositary Shares is being referred to more favorably in the media. Company Overall Sentiment Telix Pharmaceuticals Limited American Depositary Shares Positive Structure Therapeutics Positive Do insiders and institutionals believe in TLX or GPCR? 91.8% of Structure Therapeutics shares are owned by institutional investors. 9.4% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has stronger earnings & valuation, TLX or GPCR? Telix Pharmaceuticals Limited American Depositary Shares has higher revenue and earnings than Structure Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelix Pharmaceuticals Limited American Depositary Shares$783.21M7.16N/AN/AN/AStructure TherapeuticsN/AN/A-$89.62M-$0.87-27.76 SummaryStructure Therapeutics beats Telix Pharmaceuticals Limited American Depositary Shares on 6 of the 11 factors compared between the two stocks. Get Structure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GPCR vs. The Competition Export to ExcelMetricStructure TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.38B$6.49B$5.36B$8.39BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-32.638.9426.5919.72Price / SalesN/A251.55391.61116.20Price / CashN/A65.8538.2534.62Price / Book2.476.466.794.51Net Income-$89.62M$143.98M$3.23B$248.18M7 Day Performance1.39%3.16%4.03%1.14%1 Month Performance4.55%7.60%12.22%15.07%1 Year Performance-32.56%-2.36%16.76%6.59% Structure Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GPCRStructure Therapeutics2.1502 of 5 stars$24.15-2.1%$79.86+230.7%-31.1%$1.38BN/A-32.63136TLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.54-0.8%$22.00+33.0%N/A$5.59B$783.21M0.00N/APositive NewsGap UpTGTXTG Therapeutics3.8221 of 5 stars$34.98+1.8%$40.80+16.6%+115.2%$5.55B$386.39M-349.77290Positive NewsGRFSGrifols3.2195 of 5 stars$8.00+3.1%N/A+4.7%$5.50B$7.21B6.8426,300Positive NewsLNTHLantheus4.458 of 5 stars$78.25-3.7%$132.67+69.5%-7.3%$5.41B$1.54B13.02700Positive NewsAXSMAxsome Therapeutics4.7267 of 5 stars$108.30+0.7%$172.14+59.0%+39.7%$5.33B$432.16M-18.08380Positive NewsInsider TradeNUVLNuvalent2.6807 of 5 stars$73.310.0%$115.50+57.6%+7.0%$5.25BN/A-21.1340News CoveragePositive NewsLEGNLegend Biotech3.5601 of 5 stars$29.11+4.8%$74.73+156.7%-33.8%$5.10B$728.30M-30.641,070News CoverageAnalyst RevisionGap UpADMAADMA Biologics3.1806 of 5 stars$20.19+2.5%$24.25+20.1%+117.2%$4.82B$459.38M72.11530News CoveragePositive NewsGap DownPCVXVaxcyte3.117 of 5 stars$32.03+0.6%$136.50+326.2%-51.8%$4.13BN/A-6.96160News CoveragePositive NewsEarnings ReportRYTMRhythm Pharmaceuticals3.9307 of 5 stars$61.25+2.2%$75.38+23.1%+63.9%$3.90B$136.86M-14.15140 Related Companies and Tools Related Companies Telix Pharmaceuticals Limited American Depositary Shares Alternatives TG Therapeutics Alternatives Grifols Alternatives Lantheus Alternatives Axsome Therapeutics Alternatives Nuvalent Alternatives Legend Biotech Alternatives ADMA Biologics Alternatives Vaxcyte Alternatives Rhythm Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GPCR) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GPCR Stock Free GPCR Stock Alerts